Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

$292.58 +6.46 (+2.26%)

Closing price 06/3/2026 04:00 PM Eastern

Extended Trading

$293.23 +0.65 (+0.22%)

As of 05:51 AM Eastern

Compare

Alnylam Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 26 Analyst Ratings

Sell
0

Hold
6

Buy
20

Based on 26 Wall Street analysts who have issued ratings for Alnylam Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 26 analysts, 6 have given a hold rating, 18 have given a buy rating, and 2 have given a strong buy rating for ALNY.

Consensus Price Target

$463.13
58.29% Upside

According to the 26 analysts' twelve-month price targets for Alnylam Pharmaceuticals, the average price target is $463.13. The highest price target for ALNY is $566.00, while the lowest price target for ALNY is $330.00. The average price target represents a forecasted upside of 58.29% from the current price of $292.58.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for ALNY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Alnylam Pharmaceuticals and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ALNY Analyst Ratings Over Time

Type	Current Forecast 6/4/25 to 6/4/26	1 Month Ago 5/5/25 to 5/5/26	3 Months Ago 3/6/25 to 3/6/26	1 Year Ago 6/4/24 to 6/4/25
Strong Buy	2 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	18 Buy rating(s)	19 Buy rating(s)	22 Buy rating(s)	21 Buy rating(s)
Hold	6 Hold rating(s)	6 Hold rating(s)	5 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$463.13	$471.96	$477.96	$319.17
Forecasted Upside	58.29% Upside	56.74% Upside	49.06% Upside	4.54% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

ALNY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ALNY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Alnylam Pharmaceuticals Stock vs. The Competition

Type	Alnylam Pharmaceuticals	Medical Companies	Broader Market
Consensus Rating Score	2.85	2.30	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	58.29% Upside	1,802.16% Upside	15.81% Upside
News Sentiment Rating	Very Positive News See Recent ALNY News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
5/19/2026	Citigroup 4 of 5 stars	Eric Joseph Not Rated	Initiated Coverage	Buy	$380.00	+32.74%
5/5/2026	HC Wainwright 3 of 5 stars	Patrick R. Not Rated	Reiterated Rating	Buy	$510.00	+71.19%
5/4/2026	Weiss Ratings Not Rated		Upgrade	Sell (D+) ➝ Hold (C-)
5/1/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Luca Issi Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$450.00 ➝ $445.00	+47.95%
5/1/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Derek Archila Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$376.00 ➝ $377.00	+23.46%
4/13/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Brill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$515.00 ➝ $505.00	+54.44%
3/25/2026	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Keay Nakae Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$425.00	+30.25%
3/16/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Maury Raycroft Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$522.00 ➝ $330.00	+5.29%
2/17/2026	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Strong-Buy
2/17/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Whitney Ijem Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$415.00 ➝ $429.00	+36.62%
June 12: $100 Turns Into $100,000? (Ad) The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before major runs - says the window to get in early is closing fast. Brown is showing investors how to claim a stake in Elon Musk's company before it hits the public markets. Once the IPO happens, this pre-public opportunity disappears. Click here to see how to get ahead of the SpaceX IPO
2/12/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tazeen Ahmad Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy
2/12/2026	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Stringer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$529.00 ➝ $510.00	+64.71%
1/30/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Ulz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$495.00 ➝ $408.00	+19.27%
1/28/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gena Wang Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Overweight	$527.00	+48.56%
1/12/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Martin Auster Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$472.00	+18.51%
1/7/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Leland Gershell Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform	$500.00	+17.52%
12/15/2025	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mani Foroohar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Market Perform	$370.00 ➝ $351.00	-10.26%
12/11/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Paul Matteis Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$495.00 ➝ $508.00	+25.60%
10/31/2025	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Edward Tenthoff Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$449.00 ➝ $489.00	+8.21%
10/13/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jessica Fye Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$475.00 ➝ $473.00	+3.03%
9/16/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Salveen Richter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$504.00 ➝ $566.00	+22.67%
9/11/2025	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Liisa Bayko Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$280.00 ➝ $515.05	+9.93%
9/5/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kostas Biliouris Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$450.00 ➝ $470.00	+3.66%
8/4/2025	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andy Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Underperform ➝ Peer Perform
8/1/2025	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Greg Harrison Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Sector Outperform	$342.00 ➝ $450.00	+12.00%
8/1/2025	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eliana Merle Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$403.00 ➝ $550.00	+38.02%
3/31/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joshua Smith Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$353.00	+31.49%
3/21/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
1/7/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Outperform	$314.00 ➝ $310.00	+31.53%
10/21/2024	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$282.00 ➝ $371.00	+25.37%
10/11/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Neutral	$220.00 ➝ $220.00	-21.77%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:54 AM ET.

Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, May 29, 2026. Please send any questions or comments about these Alnylam Pharmaceuticals pros and cons to contact@marketbeat.com.

Alnylam Pharmaceuticals
Bull Case

Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.:

The current stock price is around $294, which may present a buying opportunity for investors looking for potential growth in the biopharmaceutical sector.
Alnylam Pharmaceuticals, Inc. has received multiple "buy" ratings from analysts, indicating strong confidence in the company's future performance.
Recent upgrades in analyst ratings, including a shift from "hold" to "buy," suggest positive sentiment and potential for stock appreciation.
The company has a robust pipeline focused on RNA interference therapeutics, which positions it well for future revenue growth as these products reach the market.
Institutional investors hold a significant majority of the stock, which often indicates confidence in the company's long-term prospects and stability.

Alnylam Pharmaceuticals
Bear Case

Investors should be bearish about investing in Alnylam Pharmaceuticals, Inc. for these reasons:

Insider selling has occurred recently, with executives selling over 21,000 shares, which may raise concerns about the company's future performance.
The stock has experienced volatility, with a 52-week high of $495 and a low of $284, indicating potential risks associated with price fluctuations.
Analysts have adjusted target prices downward, which could signal caution regarding the company's near-term growth prospects.
The company has a high price-to-earnings (P/E) ratio, suggesting that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
With corporate insiders owning only 0.86% of the stock, there may be concerns about alignment between management and shareholder interests.

ALNY Forecast - Frequently Asked Questions

According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for Alnylam Pharmaceuticals is $463.13, with a high forecast of $566.00 and a low forecast of $330.00.

26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 6 hold ratings, 18 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALNY shares.

According to analysts, Alnylam Pharmaceuticals's stock has a predicted upside of 58.29% based on their 12-month stock forecasts.

Over the previous 90 days, Alnylam Pharmaceuticals's stock had 2 upgrades and 1 downgrade by analysts.

Alnylam Pharmaceuticals has been rated by research analysts at Chardan Capital, Citigroup, HC Wainwright, Jefferies Financial Group, Royal Bank Of Canada, Truist Financial, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Alnylam Pharmaceuticals more than other "medical" companies. The consensus rating for Alnylam Pharmaceuticals is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how ALNY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Alnylam Pharmaceuticals Recommendations

This page (NASDAQ:ALNY) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

Alnylam Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

ALNY Analyst Ratings Over Time

ALNY Analyst Recommendations By Month

ALNY Price Targets by Month

Alnylam Pharmaceuticals Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained

Alnylam Pharmaceuticals
Bull Case

Alnylam Pharmaceuticals
Bear Case

ALNY Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Alnylam Pharmaceuticals Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

Alnylam Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

ALNY Analyst Ratings Over Time

ALNY Analyst Recommendations By Month

ALNY Price Targets by Month

Alnylam Pharmaceuticals Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained

Alnylam Pharmaceuticals Bull Case

Alnylam Pharmaceuticals Bear Case

ALNY Forecast - Frequently Asked Questions

What is Alnylam Pharmaceuticals' forecast for 2026?

Should I buy or sell Alnylam Pharmaceuticals stock right now?

Does Alnylam Pharmaceuticals's stock price have much upside?

Has Alnylam Pharmaceuticals been upgraded or downgraded by Wall Street analysts recently?

What analysts cover Alnylam Pharmaceuticals?

Do Wall Street analysts like Alnylam Pharmaceuticals more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Alnylam Pharmaceuticals Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Alnylam Pharmaceuticals
Bull Case

Alnylam Pharmaceuticals
Bear Case